Channels - Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients :: FRELIP Discovery

Similar Items: Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients

Quick Look
Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer
Quick Look
Expression and functional role of cyclooxygenase enzymes in cervical carcinoma
Quick Look
Programmed cell death-ligand 1 (PD-L1) expression in HIV-associated diffuse large B-cell lymphoma – role and regulation
Quick Look
Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy
Quick Look
Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma
Quick Look
Bone involvement in patients with cervical carcinoma – a single institution cohort study
Quick Look
The role of seminal plasma in cervical carcinoma
Quick Look
Correlating the expression levels of COBRA1 (co-factor of BRCA1) with hepatocellular carcinoma development in Egyptian patients
Quick Look
The Prognostic Value of Circulating Stem Cells Expressing PD-L1 in Patients with Hepatocellular Carcinoma
Quick Look
Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside
Quick Look
The role of seminal fluid in cervical squamous carcinoma progression: Impact on cell proliferation, EMT, motility and gene expression
Quick Look
Anlotinib Combined with Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 9 Hydrochloride Suppresses Colorectal Cancer Progression by Inducing Neovascularization and Reprogramming the Tumor Immune Microenvironment in MSS Murine Model
Quick Look
Development and Characterization of recombinant immunotoxins for cervical carcinoma
Quick Look
Research Progress of HER2 in Cervical Carcinoma
Quick Look
Prognostic and Predict Value of Peripheral Blood Circulating Tumor Cells Programmed Death‐Ligand 1 Expression and F‐18‐Fluorodeoxyglucose Metabolic Parameters in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Quick Look
Evaluating the role of PLGF and VEGFR-1/ Flt-1 in the development of cervical intraepithelial neoplasia and invasive cervical carcinoma in the background of HIV infection in women living in South Africa
Quick Look
Expression and regulation of the nuclear transport proteins, Crm1 and Kpnß1, in cervical cancer and transformed cells
Quick Look
Proteomic studies on patient responses to chemotherapy, radiotherapy and immunotherapy in cancers
Quick Look
Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors
Quick Look
Real-World Predictors of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: The Emerging Role of the Urologist in Immuno-Oncology
Quick Look
Investigation of microRNA expression in thyroid carcinoma among South Africa patients
Quick Look
Multimodal Modeling Distinguishes Treatment Response from Overall Survival in Hepatocellular Carcinoma Receiving Combined Interventional and Targeted Immunotherapy
Quick Look
BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma
Quick Look
Prognostic Value of UBE2S, HIF-1α, and FOXM1 Expression in Esophageal Squamous Cell Carcinoma